|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis显示文摘BACKGROUND Different histological growth patterns(HGPs)of colorectal carcinoma(CRC)liver metastasis are associated with patients’prognosis and response to antiangiogenic therapy.However,the relationship between HGPs of liver metastasis and clinicopathological and genomic characteristics of primary cancer has not been well established.AIM To assess whether certain clinicopathological and genomic features of primary CRC could predict the HGPs of liver metastasis.METHODS A total of 29 patients with paired resections of both primary CRC and liver metastasis were divided into two groups:A(15 cases with desmoplastic liver metastasis)and B(14 cases with replacement liver metastasis).Clinical information was obtained from patients’charts.Mismatch repair proteins,BRAFV600E,and PD-L1 were evaluated by immunohistochemistry.Five cases were selected randomly from each group for whole exome sequencing(WES)analysis.RESULTS In the primary tumor,expanding growth pattern,low tumor budding score(TBS),and Crohn’s disease-like response(CDR)were associated with desmoplastic liver metastasis and better overall survival,whereas infiltrating growth pattern alone of primary carcinoma could predict the replacement liver metastasis and worse overall survival(P<0.05).On WES analysis,primary carcinoma with desmoplastic liver metastasis showed mutations in APC(4/5);TP53(3/5);KRAS,PIK3CA,and FAT4(2/5);BRCA-1,BRCA2,BRAF,and DNAH5(1/5),whereas primary carcinoma with replacement liver metastasis showed mutations in APC and TP53(3/5);KRAS,FAT4,DNH5,SMAD,ERBB2,ERBB3,LRP1,and SDK1(1/5).CONCLUSION The HGPs,TBS,and CDR of primary CRC as well as the presence of specific genetic mutations such as those in PIK3CA could be used to predict the HGPs of liver metastasis,response to therapy,and patients’prognosis. | Jing-Bo Wu Ali Lopez Sarmiento Pierre-Olivier Fiset Anthula Lazaris Peter Metrakos Stephanie Petrillo Zu-Hua Gao | 2019 | World Journal of Gastroenterology2019，25，26： | 5 |
| 2 | Non-alcoholic fatty liver disease-a chronic disease of the 21^(st) century显示文摘Non-alcoholic fatty liver disease(NAFLD) comprises a spectrum of metabolic states ranging from simple steatosis to inflammation with associated fibrosis to cirrhosis. Though accumulation of hepatic fat is not associated with a significant increase in mortality rates, hepatic inflammation is, as this augments the risk of terminal liver disease, i.e.,cirrhosis, hepatic decompensation(liver failure) and/or hepatocellular carcinoma. Disease progression is usually slow, over a decade or more and, for the most part, remains asymptomatic. Recent estimates suggest that the global prevalence of NAFLD is high, about one in four. In most cases, NAFLD overlaps with overweight, obesity,cardiovascular disease and the metabolic syndrome with numerous contributing parameters including a dysregulation of adipose tissue, insulin resistance, type 2 diabetes, changes in the gut microbiome, neuronal and hormonal dysregulation and metabolic stress. NAFLD is diagnosed incidentally, despite its high prevalence. Non-invasive imaging techniques have emerged, making it possible to determine degree of steatosis as well asfibrosis. Despite this,the benefit of routine diagnostics remains uncertain. A better understanding of the(molecular) pathogenesis of NAFLD is needed combined with long-term studies where benefits of treatment can be assessed to determine costbenefit ratios. This review summarizes the current state of knowledge and possible areas of treatment. | Peter Metrakos Tommy Nilsson | 2018 | The Journal of Biomedical Research2018，32，5： | 4 |
| 3 | Pretransplantation α-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence After Transplantation显示文摘 | Teodora C. Dumitra Sinziana Dumitra Peter P. Metrakos Jeffrey S. Barkun Prosanto Chaudhury Marc Deschênes Steven Paraskevas Mazen Hassanain Jean I. Tchervenkov | 2013 | Transplantation Journal2013，，1： | 2 |
| 4 | Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation roles in cell growth, death, and cancer显示文摘 | Boutros T Chevet E Metrakos P | 2008 | 外文期刊2008，3，： | 1 |
| 5 | Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation:roles in cell growth,death,and cancer显示文摘 | BOUTROS T CHEVET E METRAKOS P | 2008 | Pharmacol Rev2008，60，3： | 1 |
| 6 | Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation:roles in cell growth, death, and cancer显示文摘 | Boutros T Chevet E Metrakos P | 2008 | Pharmacol Rev2008，60，3： | 1 |
| 7 | Clostridium Difficile Colitis: Increasing Incidence, Risk Factors, and Outcomes in Solid Organ Transplant Recipients显示文摘 | Marylise Boutros Maha Al-Shaibi Gabriel Chan Marcelo Cantarovich Elham Rahme Steven Paraskevas Marc Deschenes Peter Ghali Philip Wong Myriam Fernandez Nadia Giannetti Renzo Cecere Mazen Hassanain Prosanto Chaudhury Peter Metrakos Jean Tchervenkov Jeffrey | 2012 | Transplantation Journal2012，，10： | 1 |
| 8 | Blood product use during orthotopic liver, t ransplantation显示文摘 | Shan WL Barkun J Metrakos P | 2004 | Can J Anaesth2004，51，10： | 1 |
| 9 | Blood product use During orthotopic liver transplantation 显示文摘 | SHAN W L BARKUN J METRAKOS P | 2004 | Can J Anaesth2004，51，： | 1 |
| 10 | Mitogen-activated protein kinase phosphatase regulation:roles in cell growth,death,and cancer显示文摘 | Boutros T Chevet C Metrakos P | 2008 | Pharmacol Rev2008，60，3： | 1 |
| 11 | An anlysis of late deaths after liver transplantation显示文摘 | Asfar S Metrakos P Fryer J | 1996 | Transplantation1996，61，： | 1 |
| 12 | Randomized clinical trial of the impact of insulin therapy on liver function in patients undergoing major liver resection显示文摘 | Hassanain M Metrakos P Fisette A | 2013 | Br J Surg2013，100，5： | 1 |
| 13 | Increased in vitro and in vivo sensitivity of BRCA2 -associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673显示文摘 | Alexandra-Zoe Andrei Anita Hall Alyssa L. Smith Claire Bascu?ana Abba Malina Ashton Connor Gulbeyaz Altinel-Omeroglu Sidong Huang Jerry Pelletier David Huntsman Steven Gallinger Atilla Omeroglu Peter Metrakos George Zogopoulos | 2015 | Cancer Letters2015，，1： | 1 |
| 14 | Analysis of late deaths after liver transplantation显示文摘 | Asfer S Metrakos P Fryer J | 1996 | Transplantation1996，61，10： | 1 |
| 15 | High-dose insulin therapy reduces potope rative liver dysfunction and complications in liver re- section patients through reduced apoptosis and altered inflamma- tion 显示文摘 | Fisette A Hassanain M Metrakos P | 2012 | J Clin Endocrinol Metab2012，97，1： | 1 |
| 16 | Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of trans-plantation显示文摘 | Mardigyan V Tchervenkov J Metrakos P | 2005 | Clin Ther2005，27，： | 1 |
| 17 | Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis显示文摘 | Rasha AlShaalan Murad Aljiffry Said Al-Busafi Peter Metrakos Mazen Hassanain | 2015 | Saudi Journal of Gastroenterology2015，，2： | 1 |
| 18 | Conversion from bladder to enteric drainage after pancreaticoduodenal transplantations显示文摘 | West M Gruessner AC Metrakos P | 1998 | Surgery1998，124，5： | 1 |
| 19 | Separation of tumor cells with dielectrophoresis-based mi- crofluidie chip 显示文摘 | ALSHAREEF M METRAKOS N PEREZ E J | 2013 | Biomicrofluidies2013，7，1： | 1 |
| 20 | Mitogen-activated protein(MAP)kinase/MAP kinase phosphatase regulation:roles in cell growth,death,and cancer显示文摘 | Tarek Boutros Eric Chevet Peter Metrakos | | 0，，03： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员